Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 18 studies | 61% ± 20% | |
eye | 8 studies | 52% ± 27% | |
lung | 6 studies | 35% ± 14% | |
heart | 5 studies | 44% ± 14% | |
peripheral blood | 3 studies | 21% ± 5% | |
liver | 3 studies | 37% ± 17% | |
intestine | 3 studies | 20% ± 3% | |
adipose | 3 studies | 44% ± 10% | |
kidney | 3 studies | 38% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5069.59 | 1445 / 1445 | 100% | 36.73 | 183 / 183 |
prostate | 100% | 4854.22 | 245 / 245 | 100% | 33.22 | 502 / 502 |
brain | 100% | 6222.21 | 2641 / 2642 | 100% | 59.88 | 705 / 705 |
lung | 100% | 4905.17 | 578 / 578 | 100% | 24.78 | 1151 / 1155 |
breast | 100% | 5757.85 | 459 / 459 | 100% | 34.36 | 1113 / 1118 |
bladder | 100% | 5146.24 | 21 / 21 | 99% | 19.81 | 501 / 504 |
ovary | 100% | 6960.03 | 180 / 180 | 99% | 23.74 | 427 / 430 |
intestine | 100% | 4681.84 | 966 / 966 | 98% | 17.96 | 519 / 527 |
uterus | 100% | 6220.19 | 170 / 170 | 98% | 20.96 | 452 / 459 |
pancreas | 99% | 2435.70 | 326 / 328 | 99% | 21.04 | 176 / 178 |
adrenal gland | 100% | 5087.14 | 258 / 258 | 98% | 21.13 | 226 / 230 |
stomach | 100% | 3456.84 | 359 / 359 | 98% | 23.23 | 280 / 286 |
kidney | 100% | 3570.97 | 89 / 89 | 98% | 23.74 | 882 / 901 |
thymus | 100% | 3336.58 | 652 / 653 | 98% | 18.86 | 591 / 605 |
skin | 100% | 4445.82 | 1808 / 1809 | 96% | 19.56 | 452 / 472 |
liver | 99% | 1742.99 | 224 / 226 | 89% | 11.01 | 360 / 406 |
adipose | 100% | 5560.80 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4828.38 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 26.09 | 29 / 29 |
muscle | 100% | 6565.93 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4036.30 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.83 | 1 / 1 |
heart | 99% | 3100.25 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 4381.84 | 913 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 19.28 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 86% | 12.13 | 69 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035357 | Biological process | peroxisome proliferator activated receptor signaling pathway |
GO_0044849 | Biological process | estrous cycle |
GO_1904179 | Biological process | positive regulation of adipose tissue development |
GO_0032355 | Biological process | response to estradiol |
GO_0021766 | Biological process | hippocampus development |
GO_0045925 | Biological process | positive regulation of female receptivity |
GO_0060179 | Biological process | male mating behavior |
GO_1904017 | Biological process | cellular response to Thyroglobulin triiodothyronine |
GO_0032870 | Biological process | cellular response to hormone stimulus |
GO_0060713 | Biological process | labyrinthine layer morphogenesis |
GO_0000435 | Biological process | positive regulation of transcription from RNA polymerase II promoter by galactose |
GO_0006338 | Biological process | chromatin remodeling |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0042789 | Biological process | mRNA transcription by RNA polymerase II |
GO_0021549 | Biological process | cerebellum development |
GO_0008584 | Biological process | male gonad development |
GO_0032526 | Biological process | response to retinoic acid |
GO_0021987 | Biological process | cerebral cortex development |
GO_0007595 | Biological process | lactation |
GO_0045666 | Biological process | positive regulation of neuron differentiation |
GO_1900076 | Biological process | regulation of cellular response to insulin stimulus |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0021854 | Biological process | hypothalamus development |
GO_0032570 | Biological process | response to progesterone |
GO_0002155 | Biological process | regulation of thyroid hormone receptor signaling pathway |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005886 | Cellular component | plasma membrane |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0005829 | Cellular component | cytosol |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0016922 | Molecular function | nuclear receptor binding |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0030331 | Molecular function | nuclear estrogen receptor binding |
GO_0046965 | Molecular function | nuclear retinoid X receptor binding |
GO_0004402 | Molecular function | histone acetyltransferase activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0030374 | Molecular function | nuclear receptor coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NCOA1 |
Protein name | Nuclear receptor coactivator 1 (NCoA-1) (EC 2.3.1.48) (Class E basic helix-loop-helix protein 74) (bHLHe74) (Protein Hin-2) (RIP160) (Renal carcinoma antigen NY-REN-52) (Steroid receptor coactivator 1) (SRC-1) Nuclear receptor coactivator 1 |
Synonyms | BHLHE74 SRC1 |
Description | FUNCTION: Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors. Displays histone acetyltransferase activity toward H3 and H4; the relevance of such activity remains however unclear. Plays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription factors. Required with NCOA2 to control energy balance between white and brown adipose tissues. Required for mediating steroid hormone response. Isoform 2 has a higher thyroid hormone-dependent transactivation activity than isoform 1 and isoform 3. . |
Accessions | ENST00000348332.8 [Q15788-1] ENST00000406961.5 [Q15788-1] ENST00000405141.5 [Q15788-2] ENST00000288599.9 [Q15788-2] B5MCN7 ENST00000395856.3 [Q15788-3] ENST00000407230.5 Q15788 |